- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00819884
To Evaluate 24-hr Glucose After OD vs BD AZD1656
May 6, 2009 updated by: AstraZeneca
A Randomised, Two Way Cross-Over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients With T2DM When Dosed OD and BD on Top of Metformin for Four Days With AZD1656
The purpose of this study is to compare the 24-hour glucose profiles in diabetic patients treated with metformin following once daily and twice daily oral dosing
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- type II diabetes patients, female with non child-bearing potential
- Type 2 Diabetes Mellitus (T2DM) diagnosis confirmed by C-peptide >0.3nmol/L and no Glutamic acid decarboxylase (GAD) antibodies at enrolment (screening)
- Treatment with metformin as single therapy for T2DM for at least 30 days prior to enrolment and the metformin dose must have been unchanged during this period
Exclusion Criteria:
- History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
- Any clinically significant abnormality identified on physical examination, laboratory test or ECG, which in the judgement of investigator would compromise the subject's safety or successful participation in the clinical study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
twice daily during 4 days
|
Oral suspension
|
Experimental: 2
once daily during 4 days
|
Oral suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose)
Time Frame: Repeated sampling during the 24 hour period on day -1, 4 and 8
|
Repeated sampling during the 24 hour period on day -1, 4 and 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability (Adverse events (AEs) during the study, blood pressure (BP), pulse rate, safety laboratory variables (incl. glucose) and investigator's interpretation of electrocardiogram (ECG)
Time Frame: Frequent measurements during the study period
|
Frequent measurements during the study period
|
Pharmacokinetic variables (Area under the plasma conc vs. time curve (AUC0-24), maximum plasma conc (Cmax), time to reach maximum plasma conc(tmax), terminal elimination half-life and apparent oral clearance
Time Frame: Repeated sampling at pre-specified timepoints on day 4 and 8
|
Repeated sampling at pre-specified timepoints on day 4 and 8
|
Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24)
Time Frame: Repeated sampling during the 24 hour period on day -1, 4 and 8
|
Repeated sampling during the 24 hour period on day -1, 4 and 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Klas Malmberg, MD, PhD, Prof.,, AstraZeneca R&D Mölndal
- Principal Investigator: Emanuel P DeNoia, M.D, Healthcare Discoveries LLC Icon Development Solutions
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
January 8, 2009
First Submitted That Met QC Criteria
January 8, 2009
First Posted (Estimate)
January 9, 2009
Study Record Updates
Last Update Posted (Estimate)
May 7, 2009
Last Update Submitted That Met QC Criteria
May 6, 2009
Last Verified
May 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1020C00017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes
-
Microbio Co LtdCompleted
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Khoo Teck Puat HospitalCompletedType II Diabetes in Subjects BMI 27 to 32Singapore
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
Clinical Trials on AZD1656
-
AstraZenecaCompleted
-
AstraZenecaCompleted
-
AstraZenecaCompleted
-
AstraZenecaCompletedType II Diabetes MellitusUnited States
-
AstraZenecaCompletedGlucose LoweringUnited States
-
AstraZenecaCompletedHealthy VolunteersUnited States
-
Queen Mary University of LondonAstraZenecaActive, not recruitingDiabetes Mellitus, Type 2 | End Stage Renal Disease | Type 2 Diabetes | Renal Transplant | Kidney Transplant; ComplicationsUnited Kingdom
-
St George Street CapitalCompletedCovid19Czechia, Romania, United Kingdom
-
AstraZenecaCompleted
-
AstraZenecaCompletedType 2 Diabetes MellitusJapan